Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 11/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24952903 | 1.00 | GCK (0.42) | GCKABL1ACACBMGLLATG4B | |
| SCHEMBL24953827 | 0.89 | GCK (0.45) | GCKABL1ACACBATG4BHPGD | |
| SCHEMBL24953806 | 0.89 | CCNE1 (0.45) | GCKMAPTCCNE1CDK2CDK5 | |
| SCHEMBL24953760 | 0.89 | CCNE1 (0.45) | GCKMAPTCCNE1CDK2CDK5 | |
| SCHEMBL24954559 | 0.88 | SCD (0.43) | ATG4BMAPT | |
| SCHEMBL24952969 | 0.87 | GCK (0.39) | GCK | |
| SCHEMBL24952895 | 0.86 | JAK2 (0.40) | GCK | |
| SCHEMBL24952912 | 0.84 | GCK (0.39) | GCKACACBCCNE1CDK2CDK5 | |
| SCHEMBL24953711 | 0.84 | PIK3CG (0.38) | ACACBMAPTCCNE1CDK2CDK5 | |
| SCHEMBL24953766 | 0.82 | GCK (0.39) | GCKHPGDMAPTCCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | GCK 1519/4885ABL1 4235/4885ACACB 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.